Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive U.S. FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product for Gaucher disease, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix announced that Dror Bashan, the Company's President and CEO, will present live at the Life Sciences Investor Forum on September 19, 2024 [1] - The event will allow real-time interaction with investors, and an archived webcast will be available for those unable to attend live [2] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, such as: - PRX–115: a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout [5] - PRX–119: a plant cell-expressed long-action DNase I for NETs-related diseases [5] - The company's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Partnerships - Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [5]